Arcturus Therapeutics is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary oral drug candidate, MDX, to treat ADHD and other cognitive dysfunctions including Fragile X Syndrome. The most common available treatments for ADHD are stimulants that increase the brain chemicals dopamine and norepinephrine. Stimulants have significant side effects, and are classified as controlled substances which have significant potential for misuse, abuse and addiction. MDX is not a stimulant, and works with a different mechanism of action. MDX is a proprietary, combined rapid onset release formulation of the chemical Pyridoxine Pyroglutamate.

CBTX is a bank holding company. Through its wholly-owned subsidiary, CommunityBank of Texas, N.A. (the Bank), the company focuses on providing commercial banking solutions to small and mid-sized businesses and personnel including attorneys, accountants and other service providers with operations in its markets. The Bank provides a range of banking products, including commercial and industrial loans, commercial real estate loans, construction and development loans, one-to-four family residential mortgage loans, multi-family residential loans consumer loans, agricultural loans, treasury services, retail deposits and a suite of online banking services.

Cohu provides semiconductor test equipment and services. The company's products include semiconductor test, which is used for wafer level and device package testing; semiconductor handlers, which are used to automate the testing and inspection of packaged semiconductor devices; thermal sub-systems, which provide temperature control of the integrated circuit during the testing process; bare board printed circuit board (PCB) test systems, which are used to test pre-assembly PCBs; interface products, which consist of test contactors and probe pins; spares and kits, which provide consumable, non-consumable and spare items; and services, which performs installations and maintenance of systems sold.

Core Molding Technologies operates in the composites market in a family of products known as structural composites. Structural composites are combinations of resins and reinforcing fibers (typically glass or carbon) that are molded to shape. The company is a manufacturer of sheet molding compound (SMC) and molder of thermoset and thermoplastic products. The company focuses on moldings and provides processes, including compression molding of SMC, glass mat thermoplastics, bulk molding compounds and direct long fiber thermoplastic, spray-up, hand-lay-up, resin transfer molding, structural foam and structural web injection molding, and reaction injection molding, utilizing dicyclopentadiene technology.

Cortexyme is a clinical stage biopharmaceutical company focused on developing therapeutics based on data supporting a new theory of the cause of Alzheimer's disease and other degenerative disorders. The company is targeting a specific, infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models. The company's proprietary main drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor.

Dropbox is a global collaboration platform that centralizes the flow of information between the products and services its users prefer. Dropbox allows individuals, teams, and organizations to collaborate. Anyone can sign up for free via the company's website or app, and upgrade to a paid subscription plan for additional features. Dropbox is a digital workspace where individuals and teams can create content, access it from anywhere, and share it with collaborators. The company also utilizes Amazon Web Services (AWS), for the remainder of its users' storage needs and to help deliver its services. These AWS datacenters are in the United States and Europe, which allows the company to localize where content is stored.

Arconic is engaged in lightweight metals engineering and manufacturing. The company's segments include: Engineered Products and Solutions, which produces products that are used mainly in the aerospace (commercial and defense), industrial, commercial transportation, and power generation end markets; Global Rolled Products, which produces aluminum sheet and plate for a variety of end markets, and also produces aseptic foil for the packaging end market; and Transportation and Construction Solutions, which produces products that are used in the commercial transportation and nonresidential building and construction end markets, and also produces aluminum products for the industrial products end market.

Mustang Bio is a clinical-stage biopharmaceutical company. In partnership with St. Jude Children's Research Hospital, the company's gene therapy program (MB-107) is being developed to treat X-linked severe combined immunodeficiency. The company is developing chimeric antigen receptor engineered T cell therapies for hematologic malignancies in partnership with the City of Hope National Medical Center targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutchinson Cancer Research Center targeting CD20 (MB-106). In addition, The company has partnered with Nationwide Children's Hospital for C134 (MB-108) in order to improve the activity of MB-101 for the treatment of patients with glioblastoma multiforme.

S&W Seed is an agricultural company engaged in breeding, growing, processing and selling agricultural seeds, primarily alfalfa seed. The company also has a commercial market presence in sunflower and maintains an active stevia development program. The company's seed platform develops and supplies germplasm designed to produce higher yields for farmers worldwide. The company's portfolio of alfalfa seed products includes varieties that, depending upon the particular variety, exhibit traits that forage hay farmers required, such as high yield, root rot resistance, lodging resistance, salt tolerance, drought tolerance, leafhopper resistance and stem nematode resistance.

Saratoga Investment is registered as non-diversified closed end management investment company and a business development company. The company's investment objective is to generate income and, to a lesser extent, capital appreciation from its investments. The company's portfolio is comprised primarily of investments in leveraged loans issued by middle market companies.